The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.

We use cookies in order to ensure that you can get the best browsing experience possible on the Council website. Certain cookies are used to obtain aggregated statistics about website visits to help ...